Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage

Executive Summary

Novartis Oncology President Bruno Strigini talks about refining the pharma major's oncology strategy and its pipeline potential.

You may also be interested in...



Novartis Oncology Strategy: Focus On The Microenvironment

As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.

Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early

Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.

Alcon Loses CEO And Eye Drugs After Dragging On Novartis Financials

Novartis is set to overhaul its eye care business Alcon after a lackluster 2015, focusing on its core Surgical and Vision Care business by cleaving its ophthalmic pharmaceuticals business and repositioning it into the Pharmaceuticals division.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel